Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
161,353
archived clinical trials in
Cancer

A Comparison Study of Two Community Outreach-Based Approaches to Increase Participation of Women Living in the Mississippi Delta in Cervical Cancer Screening
A Comparison Study of Two Community Outreach-Based Approaches to Increase Participation of Women Living in the Mississippi Delta in Cervical Cancer Screening
Status: Archived
National Cancer Institute (NCI)
mi
from
Bethesda, MD
A Comparison Study of Two Community Outreach-Based Approaches to Increase Participation of Women Living in the Mississippi Delta in Cervical Cancer Screening
A Comparison Study of Two Community Outreach-Based Approaches to Increase Participation of Women Living in the Mississippi Delta in Cervical Cancer Screening
Status: Archived
Updated: 1/1/1970
National Cancer Institute (NCI)
mi
from
Bethesda, MD
Xpress Digital Mammography System Images for Computer Aided Detection Development
A Multi-Center Clinical Study to Acquire Xpress Digital Mammography System Images for Computer Aided Detection Development
Status: Archived
Waterbury Hospital
mi
from
Waterbury, CT
Xpress Digital Mammography System Images for Computer Aided Detection Development
A Multi-Center Clinical Study to Acquire Xpress Digital Mammography System Images for Computer Aided Detection Development
Status: Archived
Updated: 1/1/1970
Waterbury Hospital
mi
from
Waterbury, CT
Xpress Digital Mammography System Images for Computer Aided Detection Development
A Multi-Center Clinical Study to Acquire Xpress Digital Mammography System Images for Computer Aided Detection Development
Status: Archived
Jackson Memorial Hospital
mi
from
Miami, FL
Xpress Digital Mammography System Images for Computer Aided Detection Development
A Multi-Center Clinical Study to Acquire Xpress Digital Mammography System Images for Computer Aided Detection Development
Status: Archived
Updated: 1/1/1970
Jackson Memorial Hospital
mi
from
Miami, FL
Xpress Digital Mammography System Images for Computer Aided Detection Development
A Multi-Center Clinical Study to Acquire Xpress Digital Mammography System Images for Computer Aided Detection Development
Status: Archived
University of Iowa
mi
from
Iowa City, IA
Xpress Digital Mammography System Images for Computer Aided Detection Development
A Multi-Center Clinical Study to Acquire Xpress Digital Mammography System Images for Computer Aided Detection Development
Status: Archived
Updated: 1/1/1970
University of Iowa
mi
from
Iowa City, IA
Xpress Digital Mammography System Images for Computer Aided Detection Development
A Multi-Center Clinical Study to Acquire Xpress Digital Mammography System Images for Computer Aided Detection Development
Status: Archived
Tulane University Medical Center
mi
from
New Orleans, LA
Xpress Digital Mammography System Images for Computer Aided Detection Development
A Multi-Center Clinical Study to Acquire Xpress Digital Mammography System Images for Computer Aided Detection Development
Status: Archived
Updated: 1/1/1970
Tulane University Medical Center
mi
from
New Orleans, LA
Xpress Digital Mammography System Images for Computer Aided Detection Development
A Multi-Center Clinical Study to Acquire Xpress Digital Mammography System Images for Computer Aided Detection Development
Status: Archived
Henry Ford Hospital
mi
from
Detroit, MI
Xpress Digital Mammography System Images for Computer Aided Detection Development
A Multi-Center Clinical Study to Acquire Xpress Digital Mammography System Images for Computer Aided Detection Development
Status: Archived
Updated: 1/1/1970
Henry Ford Hospital
mi
from
Detroit, MI
Xpress Digital Mammography System Images for Computer Aided Detection Development
A Multi-Center Clinical Study to Acquire Xpress Digital Mammography System Images for Computer Aided Detection Development
Status: Archived
University of Texas Health Science Center at Houston
mi
from
Houston, TX
Xpress Digital Mammography System Images for Computer Aided Detection Development
A Multi-Center Clinical Study to Acquire Xpress Digital Mammography System Images for Computer Aided Detection Development
Status: Archived
Updated: 1/1/1970
University of Texas Health Science Center at Houston
mi
from
Houston, TX
Dose-Ranging Study of Telintra® Tablets + Revlimid® in Patients With Non-Deletion (5q) Low to Intermediate-1 Risk Myelodysplastic Syndrome (MDS)
Phase 1 Dose-Ranging Study of Ezatiostat Hydrochloride (Telintra®, TLK199 Tablets)in Combination With Lenalidomide (Revlimid®)in Patients With Non-Deletion(5q) Low to Intermediate-1 Risk Myelodysplastic Syndrome (MDS)
Status: Archived
Mayo Clinic Phoenix
mi
from
Phoenix, AZ
Dose-Ranging Study of Telintra® Tablets + Revlimid® in Patients With Non-Deletion (5q) Low to Intermediate-1 Risk Myelodysplastic Syndrome (MDS)
Phase 1 Dose-Ranging Study of Ezatiostat Hydrochloride (Telintra®, TLK199 Tablets)in Combination With Lenalidomide (Revlimid®)in Patients With Non-Deletion(5q) Low to Intermediate-1 Risk Myelodysplastic Syndrome (MDS)
Status: Archived
Updated: 1/1/1970
Mayo Clinic Phoenix
mi
from
Phoenix, AZ
Dose-Ranging Study of Telintra® Tablets + Revlimid® in Patients With Non-Deletion (5q) Low to Intermediate-1 Risk Myelodysplastic Syndrome (MDS)
Phase 1 Dose-Ranging Study of Ezatiostat Hydrochloride (Telintra®, TLK199 Tablets)in Combination With Lenalidomide (Revlimid®)in Patients With Non-Deletion(5q) Low to Intermediate-1 Risk Myelodysplastic Syndrome (MDS)
Status: Archived
Cardinal Bernardin Cancer Center at Loyola University Medical Center
mi
from
Maywood, IL
Dose-Ranging Study of Telintra® Tablets + Revlimid® in Patients With Non-Deletion (5q) Low to Intermediate-1 Risk Myelodysplastic Syndrome (MDS)
Phase 1 Dose-Ranging Study of Ezatiostat Hydrochloride (Telintra®, TLK199 Tablets)in Combination With Lenalidomide (Revlimid®)in Patients With Non-Deletion(5q) Low to Intermediate-1 Risk Myelodysplastic Syndrome (MDS)
Status: Archived
Updated: 1/1/1970
Cardinal Bernardin Cancer Center at Loyola University Medical Center
mi
from
Maywood, IL
Dose-Ranging Study of Telintra® Tablets + Revlimid® in Patients With Non-Deletion (5q) Low to Intermediate-1 Risk Myelodysplastic Syndrome (MDS)
Phase 1 Dose-Ranging Study of Ezatiostat Hydrochloride (Telintra®, TLK199 Tablets)in Combination With Lenalidomide (Revlimid®)in Patients With Non-Deletion(5q) Low to Intermediate-1 Risk Myelodysplastic Syndrome (MDS)
Status: Archived
Center for Cancer & Blood Disorders
mi
from
Bethesda, MD
Dose-Ranging Study of Telintra® Tablets + Revlimid® in Patients With Non-Deletion (5q) Low to Intermediate-1 Risk Myelodysplastic Syndrome (MDS)
Phase 1 Dose-Ranging Study of Ezatiostat Hydrochloride (Telintra®, TLK199 Tablets)in Combination With Lenalidomide (Revlimid®)in Patients With Non-Deletion(5q) Low to Intermediate-1 Risk Myelodysplastic Syndrome (MDS)
Status: Archived
Updated: 1/1/1970
Center for Cancer & Blood Disorders
mi
from
Bethesda, MD
Dose-Ranging Study of Telintra® Tablets + Revlimid® in Patients With Non-Deletion (5q) Low to Intermediate-1 Risk Myelodysplastic Syndrome (MDS)
Phase 1 Dose-Ranging Study of Ezatiostat Hydrochloride (Telintra®, TLK199 Tablets)in Combination With Lenalidomide (Revlimid®)in Patients With Non-Deletion(5q) Low to Intermediate-1 Risk Myelodysplastic Syndrome (MDS)
Status: Archived
Dana-Farber Cancer Institute
mi
from
Boston, MA
Dose-Ranging Study of Telintra® Tablets + Revlimid® in Patients With Non-Deletion (5q) Low to Intermediate-1 Risk Myelodysplastic Syndrome (MDS)
Phase 1 Dose-Ranging Study of Ezatiostat Hydrochloride (Telintra®, TLK199 Tablets)in Combination With Lenalidomide (Revlimid®)in Patients With Non-Deletion(5q) Low to Intermediate-1 Risk Myelodysplastic Syndrome (MDS)
Status: Archived
Updated: 1/1/1970
Dana-Farber Cancer Institute
mi
from
Boston, MA
Dose-Ranging Study of Telintra® Tablets + Revlimid® in Patients With Non-Deletion (5q) Low to Intermediate-1 Risk Myelodysplastic Syndrome (MDS)
Phase 1 Dose-Ranging Study of Ezatiostat Hydrochloride (Telintra®, TLK199 Tablets)in Combination With Lenalidomide (Revlimid®)in Patients With Non-Deletion(5q) Low to Intermediate-1 Risk Myelodysplastic Syndrome (MDS)
Status: Archived
Columbia Presbyterian Med Ctr
mi
from
New York, NY
Dose-Ranging Study of Telintra® Tablets + Revlimid® in Patients With Non-Deletion (5q) Low to Intermediate-1 Risk Myelodysplastic Syndrome (MDS)
Phase 1 Dose-Ranging Study of Ezatiostat Hydrochloride (Telintra®, TLK199 Tablets)in Combination With Lenalidomide (Revlimid®)in Patients With Non-Deletion(5q) Low to Intermediate-1 Risk Myelodysplastic Syndrome (MDS)
Status: Archived
Updated: 1/1/1970
Columbia Presbyterian Med Ctr
mi
from
New York, NY
Dose-Ranging Study of Telintra® Tablets + Revlimid® in Patients With Non-Deletion (5q) Low to Intermediate-1 Risk Myelodysplastic Syndrome (MDS)
Phase 1 Dose-Ranging Study of Ezatiostat Hydrochloride (Telintra®, TLK199 Tablets)in Combination With Lenalidomide (Revlimid®)in Patients With Non-Deletion(5q) Low to Intermediate-1 Risk Myelodysplastic Syndrome (MDS)
Status: Archived
Strong Memorial Hospital (University of Rochester School of Medicine)
mi
from
Rochester, NY
Dose-Ranging Study of Telintra® Tablets + Revlimid® in Patients With Non-Deletion (5q) Low to Intermediate-1 Risk Myelodysplastic Syndrome (MDS)
Phase 1 Dose-Ranging Study of Ezatiostat Hydrochloride (Telintra®, TLK199 Tablets)in Combination With Lenalidomide (Revlimid®)in Patients With Non-Deletion(5q) Low to Intermediate-1 Risk Myelodysplastic Syndrome (MDS)
Status: Archived
Updated: 1/1/1970
Strong Memorial Hospital (University of Rochester School of Medicine)
mi
from
Rochester, NY
Dose-Ranging Study of Telintra® Tablets + Revlimid® in Patients With Non-Deletion (5q) Low to Intermediate-1 Risk Myelodysplastic Syndrome (MDS)
Phase 1 Dose-Ranging Study of Ezatiostat Hydrochloride (Telintra®, TLK199 Tablets)in Combination With Lenalidomide (Revlimid®)in Patients With Non-Deletion(5q) Low to Intermediate-1 Risk Myelodysplastic Syndrome (MDS)
Status: Archived
Cleveland Clinic Florida
mi
from
Weston, FL
Dose-Ranging Study of Telintra® Tablets + Revlimid® in Patients With Non-Deletion (5q) Low to Intermediate-1 Risk Myelodysplastic Syndrome (MDS)
Phase 1 Dose-Ranging Study of Ezatiostat Hydrochloride (Telintra®, TLK199 Tablets)in Combination With Lenalidomide (Revlimid®)in Patients With Non-Deletion(5q) Low to Intermediate-1 Risk Myelodysplastic Syndrome (MDS)
Status: Archived
Updated: 1/1/1970
Cleveland Clinic Florida
mi
from
Weston, FL
Dose-Ranging Study of Telintra® Tablets + Revlimid® in Patients With Non-Deletion (5q) Low to Intermediate-1 Risk Myelodysplastic Syndrome (MDS)
Phase 1 Dose-Ranging Study of Ezatiostat Hydrochloride (Telintra®, TLK199 Tablets)in Combination With Lenalidomide (Revlimid®)in Patients With Non-Deletion(5q) Low to Intermediate-1 Risk Myelodysplastic Syndrome (MDS)
Status: Archived
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Dose-Ranging Study of Telintra® Tablets + Revlimid® in Patients With Non-Deletion (5q) Low to Intermediate-1 Risk Myelodysplastic Syndrome (MDS)
Phase 1 Dose-Ranging Study of Ezatiostat Hydrochloride (Telintra®, TLK199 Tablets)in Combination With Lenalidomide (Revlimid®)in Patients With Non-Deletion(5q) Low to Intermediate-1 Risk Myelodysplastic Syndrome (MDS)
Status: Archived
Updated: 1/1/1970
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Dose-Ranging Study of Telintra® Tablets + Revlimid® in Patients With Non-Deletion (5q) Low to Intermediate-1 Risk Myelodysplastic Syndrome (MDS)
Phase 1 Dose-Ranging Study of Ezatiostat Hydrochloride (Telintra®, TLK199 Tablets)in Combination With Lenalidomide (Revlimid®)in Patients With Non-Deletion(5q) Low to Intermediate-1 Risk Myelodysplastic Syndrome (MDS)
Status: Archived
Cancer Care Centers of South Texas
mi
from
San Antonio, TX
Dose-Ranging Study of Telintra® Tablets + Revlimid® in Patients With Non-Deletion (5q) Low to Intermediate-1 Risk Myelodysplastic Syndrome (MDS)
Phase 1 Dose-Ranging Study of Ezatiostat Hydrochloride (Telintra®, TLK199 Tablets)in Combination With Lenalidomide (Revlimid®)in Patients With Non-Deletion(5q) Low to Intermediate-1 Risk Myelodysplastic Syndrome (MDS)
Status: Archived
Updated: 1/1/1970
Cancer Care Centers of South Texas
mi
from
San Antonio, TX
Feasibility Study: Comparison of Performance Status With Objective Physical Activity Monitors
OS09328 Feasibility Study: Comparison of Performance Status With Objective Physical Activity Monitors
Status: Archived
University of Wisconsin-Madison, Department of Dermatology
mi
from
Madison, WI
Feasibility Study: Comparison of Performance Status With Objective Physical Activity Monitors
OS09328 Feasibility Study: Comparison of Performance Status With Objective Physical Activity Monitors
Status: Archived
Updated: 1/1/1970
University of Wisconsin-Madison, Department of Dermatology
mi
from
Madison, WI
Dose Escalation Study of RAD001 in Combination w/Chemotherapy & Radiation in Patients With NSCLC
A Phase I Dose Escalation Study of RAD001 in Combination With Chemotherapy and Radiation in Patients With NSCLC
Status: Archived
University of Chicago Medical Center
mi
from
Chicago, IL
Dose Escalation Study of RAD001 in Combination w/Chemotherapy & Radiation in Patients With NSCLC
A Phase I Dose Escalation Study of RAD001 in Combination With Chemotherapy and Radiation in Patients With NSCLC
Status: Archived
Updated: 1/1/1970
University of Chicago Medical Center
mi
from
Chicago, IL
A Urinary Tumor Marker (Kidney Injury Molecule-1) for the Detection of Renal Cell Carcinoma
A Urinary Tumor Marker (Kidney Injury Molecule-1) for the Detection of Renal Cell Carcinoma
Status: Archived
Wiiliam Beaumont Hospital
mi
from
Royal oak, MI
A Urinary Tumor Marker (Kidney Injury Molecule-1) for the Detection of Renal Cell Carcinoma
A Urinary Tumor Marker (Kidney Injury Molecule-1) for the Detection of Renal Cell Carcinoma
Status: Archived
Updated: 1/1/1970
Wiiliam Beaumont Hospital
mi
from
Royal oak, MI
Efficacy and Safety of Gadobutrol 1.0 Molar (Gadovist) for Breast MRI
An Open Label, Multi-center, Phase 3 Study With Corresponding Blinded Image Reading to Determine the Efficacy and Safety of a Single Intravenous Injection of 0.1 mmol/kg Body Weight of Gadobutrol 1.0 Molar (Gadovist®) in Patients With Newly Diagnosed Breast Cancer Referred for Contrast-enhanced Breast MRI
Status: Archived
Clinical Trial Facility
mi
from
Santa Clara, CA
Efficacy and Safety of Gadobutrol 1.0 Molar (Gadovist) for Breast MRI
An Open Label, Multi-center, Phase 3 Study With Corresponding Blinded Image Reading to Determine the Efficacy and Safety of a Single Intravenous Injection of 0.1 mmol/kg Body Weight of Gadobutrol 1.0 Molar (Gadovist®) in Patients With Newly Diagnosed Breast Cancer Referred for Contrast-enhanced Breast MRI
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Santa Clara, CA
Efficacy and Safety of Gadobutrol 1.0 Molar (Gadovist) for Breast MRI
An Open Label, Multi-center, Phase 3 Study With Corresponding Blinded Image Reading to Determine the Efficacy and Safety of a Single Intravenous Injection of 0.1 mmol/kg Body Weight of Gadobutrol 1.0 Molar (Gadovist®) in Patients With Newly Diagnosed Breast Cancer Referred for Contrast-enhanced Breast MRI
Status: Archived
Clinical Trial Facility
mi
from
Centralia, IL
Efficacy and Safety of Gadobutrol 1.0 Molar (Gadovist) for Breast MRI
An Open Label, Multi-center, Phase 3 Study With Corresponding Blinded Image Reading to Determine the Efficacy and Safety of a Single Intravenous Injection of 0.1 mmol/kg Body Weight of Gadobutrol 1.0 Molar (Gadovist®) in Patients With Newly Diagnosed Breast Cancer Referred for Contrast-enhanced Breast MRI
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Centralia, IL
Efficacy and Safety of Gadobutrol 1.0 Molar (Gadovist) for Breast MRI
An Open Label, Multi-center, Phase 3 Study With Corresponding Blinded Image Reading to Determine the Efficacy and Safety of a Single Intravenous Injection of 0.1 mmol/kg Body Weight of Gadobutrol 1.0 Molar (Gadovist®) in Patients With Newly Diagnosed Breast Cancer Referred for Contrast-enhanced Breast MRI
Status: Archived
Clinical Trial Facility
mi
from
Boston, MA
Efficacy and Safety of Gadobutrol 1.0 Molar (Gadovist) for Breast MRI
An Open Label, Multi-center, Phase 3 Study With Corresponding Blinded Image Reading to Determine the Efficacy and Safety of a Single Intravenous Injection of 0.1 mmol/kg Body Weight of Gadobutrol 1.0 Molar (Gadovist®) in Patients With Newly Diagnosed Breast Cancer Referred for Contrast-enhanced Breast MRI
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Boston, MA
Efficacy and Safety of Gadobutrol 1.0 Molar (Gadovist) for Breast MRI
An Open Label, Multi-center, Phase 3 Study With Corresponding Blinded Image Reading to Determine the Efficacy and Safety of a Single Intravenous Injection of 0.1 mmol/kg Body Weight of Gadobutrol 1.0 Molar (Gadovist®) in Patients With Newly Diagnosed Breast Cancer Referred for Contrast-enhanced Breast MRI
Status: Archived
Clinical Trial Facility
mi
from
Austin, TX
Efficacy and Safety of Gadobutrol 1.0 Molar (Gadovist) for Breast MRI
An Open Label, Multi-center, Phase 3 Study With Corresponding Blinded Image Reading to Determine the Efficacy and Safety of a Single Intravenous Injection of 0.1 mmol/kg Body Weight of Gadobutrol 1.0 Molar (Gadovist®) in Patients With Newly Diagnosed Breast Cancer Referred for Contrast-enhanced Breast MRI
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Austin, TX
Determining the Lymphokine Activated Killer (LAK) Cytotoxicity Present in Patients Undergoing Interleukin-2 Therapy
Lymphokine Activated Killer (LAK) Cell Activity Against Cell Lines In-vitro of LAK Generated in Vivo by Pulse Interleukin-2 Therapy
Status: Archived
Loma Linda Medical Center
mi
from
Loma Linda, CA
Determining the Lymphokine Activated Killer (LAK) Cytotoxicity Present in Patients Undergoing Interleukin-2 Therapy
Lymphokine Activated Killer (LAK) Cell Activity Against Cell Lines In-vitro of LAK Generated in Vivo by Pulse Interleukin-2 Therapy
Status: Archived
Updated: 1/1/1970
Loma Linda Medical Center
mi
from
Loma Linda, CA
Safety of BKM120 Monotherapy in Advanced Solid Tumor Patients
A Phase IA, Multicenter, Open-label Dose Escalation Study of BKM120, Administered Orally in Adult Patients With Advanced Solid Malignancies
Status: Archived
City of Hope Comprehensive Cancer Center
mi
from
Duarte, CA
Safety of BKM120 Monotherapy in Advanced Solid Tumor Patients
A Phase IA, Multicenter, Open-label Dose Escalation Study of BKM120, Administered Orally in Adult Patients With Advanced Solid Malignancies
Status: Archived
Updated: 1/1/1970
City of Hope Comprehensive Cancer Center
mi
from
Duarte, CA
Safety of BKM120 Monotherapy in Advanced Solid Tumor Patients
A Phase IA, Multicenter, Open-label Dose Escalation Study of BKM120, Administered Orally in Adult Patients With Advanced Solid Malignancies
Status: Archived
Sarah Cannon Cancer Center
mi
from
Nashville, TN
Safety of BKM120 Monotherapy in Advanced Solid Tumor Patients
A Phase IA, Multicenter, Open-label Dose Escalation Study of BKM120, Administered Orally in Adult Patients With Advanced Solid Malignancies
Status: Archived
Updated: 1/1/1970
Sarah Cannon Cancer Center
mi
from
Nashville, TN
Ovarian Cancer Vaccine for Patients in Remission
A Randomized, Open-Label Phase IIb Trial of Maintenance Therapy With a MUC1 Dendritic Cell Vaccine (CVac) for Epithelial Ovarian Cancer Patients in First or Second Remission
Status: Archived
California Cancer Care
mi
from
Greenbrae, CA
Ovarian Cancer Vaccine for Patients in Remission
A Randomized, Open-Label Phase IIb Trial of Maintenance Therapy With a MUC1 Dendritic Cell Vaccine (CVac) for Epithelial Ovarian Cancer Patients in First or Second Remission
Status: Archived
Updated: 1/1/1970
California Cancer Care
mi
from
Greenbrae, CA
Ovarian Cancer Vaccine for Patients in Remission
A Randomized, Open-Label Phase IIb Trial of Maintenance Therapy With a MUC1 Dendritic Cell Vaccine (CVac) for Epithelial Ovarian Cancer Patients in First or Second Remission
Status: Archived
Scripps Cancer Center
mi
from
San Diego, CA
Ovarian Cancer Vaccine for Patients in Remission
A Randomized, Open-Label Phase IIb Trial of Maintenance Therapy With a MUC1 Dendritic Cell Vaccine (CVac) for Epithelial Ovarian Cancer Patients in First or Second Remission
Status: Archived
Updated: 1/1/1970
Scripps Cancer Center
mi
from
San Diego, CA
Ovarian Cancer Vaccine for Patients in Remission
A Randomized, Open-Label Phase IIb Trial of Maintenance Therapy With a MUC1 Dendritic Cell Vaccine (CVac) for Epithelial Ovarian Cancer Patients in First or Second Remission
Status: Archived
Stanford University Dept. of Medicine-Oncology
mi
from
Stanford, CA
Ovarian Cancer Vaccine for Patients in Remission
A Randomized, Open-Label Phase IIb Trial of Maintenance Therapy With a MUC1 Dendritic Cell Vaccine (CVac) for Epithelial Ovarian Cancer Patients in First or Second Remission
Status: Archived
Updated: 1/1/1970
Stanford University Dept. of Medicine-Oncology
mi
from
Stanford, CA
Ovarian Cancer Vaccine for Patients in Remission
A Randomized, Open-Label Phase IIb Trial of Maintenance Therapy With a MUC1 Dendritic Cell Vaccine (CVac) for Epithelial Ovarian Cancer Patients in First or Second Remission
Status: Archived
Collaborative Research Group
mi
from
Boynton Beach, FL
Ovarian Cancer Vaccine for Patients in Remission
A Randomized, Open-Label Phase IIb Trial of Maintenance Therapy With a MUC1 Dendritic Cell Vaccine (CVac) for Epithelial Ovarian Cancer Patients in First or Second Remission
Status: Archived
Updated: 1/1/1970
Collaborative Research Group
mi
from
Boynton Beach, FL
Ovarian Cancer Vaccine for Patients in Remission
A Randomized, Open-Label Phase IIb Trial of Maintenance Therapy With a MUC1 Dendritic Cell Vaccine (CVac) for Epithelial Ovarian Cancer Patients in First or Second Remission
Status: Archived
Northside Hospital
mi
from
Atlanta, GA
Ovarian Cancer Vaccine for Patients in Remission
A Randomized, Open-Label Phase IIb Trial of Maintenance Therapy With a MUC1 Dendritic Cell Vaccine (CVac) for Epithelial Ovarian Cancer Patients in First or Second Remission
Status: Archived
Updated: 1/1/1970
Northside Hospital
mi
from
Atlanta, GA
Ovarian Cancer Vaccine for Patients in Remission
A Randomized, Open-Label Phase IIb Trial of Maintenance Therapy With a MUC1 Dendritic Cell Vaccine (CVac) for Epithelial Ovarian Cancer Patients in First or Second Remission
Status: Archived
Indiana Univeristy School of Medicine
mi
from
Indianapolis, IN
Ovarian Cancer Vaccine for Patients in Remission
A Randomized, Open-Label Phase IIb Trial of Maintenance Therapy With a MUC1 Dendritic Cell Vaccine (CVac) for Epithelial Ovarian Cancer Patients in First or Second Remission
Status: Archived
Updated: 1/1/1970
Indiana Univeristy School of Medicine
mi
from
Indianapolis, IN
Ovarian Cancer Vaccine for Patients in Remission
A Randomized, Open-Label Phase IIb Trial of Maintenance Therapy With a MUC1 Dendritic Cell Vaccine (CVac) for Epithelial Ovarian Cancer Patients in First or Second Remission
Status: Archived
Morristown Memorial Hospital
mi
from
Morristown, NJ
Ovarian Cancer Vaccine for Patients in Remission
A Randomized, Open-Label Phase IIb Trial of Maintenance Therapy With a MUC1 Dendritic Cell Vaccine (CVac) for Epithelial Ovarian Cancer Patients in First or Second Remission
Status: Archived
Updated: 1/1/1970
Morristown Memorial Hospital
mi
from
Morristown, NJ
Ovarian Cancer Vaccine for Patients in Remission
A Randomized, Open-Label Phase IIb Trial of Maintenance Therapy With a MUC1 Dendritic Cell Vaccine (CVac) for Epithelial Ovarian Cancer Patients in First or Second Remission
Status: Archived
New York Downtown Hospital
mi
from
New York, NY
Ovarian Cancer Vaccine for Patients in Remission
A Randomized, Open-Label Phase IIb Trial of Maintenance Therapy With a MUC1 Dendritic Cell Vaccine (CVac) for Epithelial Ovarian Cancer Patients in First or Second Remission
Status: Archived
Updated: 1/1/1970
New York Downtown Hospital
mi
from
New York, NY
Ovarian Cancer Vaccine for Patients in Remission
A Randomized, Open-Label Phase IIb Trial of Maintenance Therapy With a MUC1 Dendritic Cell Vaccine (CVac) for Epithelial Ovarian Cancer Patients in First or Second Remission
Status: Archived
Duke Univ Med Ctr
mi
from
Durham, NC
Ovarian Cancer Vaccine for Patients in Remission
A Randomized, Open-Label Phase IIb Trial of Maintenance Therapy With a MUC1 Dendritic Cell Vaccine (CVac) for Epithelial Ovarian Cancer Patients in First or Second Remission
Status: Archived
Updated: 1/1/1970
Duke Univ Med Ctr
mi
from
Durham, NC
Ovarian Cancer Vaccine for Patients in Remission
A Randomized, Open-Label Phase IIb Trial of Maintenance Therapy With a MUC1 Dendritic Cell Vaccine (CVac) for Epithelial Ovarian Cancer Patients in First or Second Remission
Status: Archived
The Cleveland Clinic
mi
from
Cleveland, OH
Ovarian Cancer Vaccine for Patients in Remission
A Randomized, Open-Label Phase IIb Trial of Maintenance Therapy With a MUC1 Dendritic Cell Vaccine (CVac) for Epithelial Ovarian Cancer Patients in First or Second Remission
Status: Archived
Updated: 1/1/1970
The Cleveland Clinic
mi
from
Cleveland, OH
Ovarian Cancer Vaccine for Patients in Remission
A Randomized, Open-Label Phase IIb Trial of Maintenance Therapy With a MUC1 Dendritic Cell Vaccine (CVac) for Epithelial Ovarian Cancer Patients in First or Second Remission
Status: Archived
Medical University of South Carolina
mi
from
Charleston, SC
Ovarian Cancer Vaccine for Patients in Remission
A Randomized, Open-Label Phase IIb Trial of Maintenance Therapy With a MUC1 Dendritic Cell Vaccine (CVac) for Epithelial Ovarian Cancer Patients in First or Second Remission
Status: Archived
Updated: 1/1/1970
Medical University of South Carolina
mi
from
Charleston, SC
Ovarian Cancer Vaccine for Patients in Remission
A Randomized, Open-Label Phase IIb Trial of Maintenance Therapy With a MUC1 Dendritic Cell Vaccine (CVac) for Epithelial Ovarian Cancer Patients in First or Second Remission
Status: Archived
University of Washington Medical Center
mi
from
Seattle, WA
Ovarian Cancer Vaccine for Patients in Remission
A Randomized, Open-Label Phase IIb Trial of Maintenance Therapy With a MUC1 Dendritic Cell Vaccine (CVac) for Epithelial Ovarian Cancer Patients in First or Second Remission
Status: Archived
Updated: 1/1/1970
University of Washington Medical Center
mi
from
Seattle, WA
Dose Escalating Study With BAY43-9006 With Carboplatin, Paclitaxel and Bevacizumab in Untreated Stage IIIb Non-small Cell Lung Cancer (NSCLC)
Study of BAY43-9006 (Sorafenib) in Combination With Carboplatin, Paclitaxel and Bevacizumab in Previously Untreated Patients With Stage IIIB (With Malignant Pleural Effusions) or Stage IV Non-small Cell Lung Cancer (NSCLC)
Status: Archived
Hematology Oncology Associates of the Quad Cities
mi
from
Bettendorf, IA
Dose Escalating Study With BAY43-9006 With Carboplatin, Paclitaxel and Bevacizumab in Untreated Stage IIIb Non-small Cell Lung Cancer (NSCLC)
Study of BAY43-9006 (Sorafenib) in Combination With Carboplatin, Paclitaxel and Bevacizumab in Previously Untreated Patients With Stage IIIB (With Malignant Pleural Effusions) or Stage IV Non-small Cell Lung Cancer (NSCLC)
Status: Archived
Updated: 1/1/1970
Hematology Oncology Associates of the Quad Cities
mi
from
Bettendorf, IA
Dose Escalating Study With BAY43-9006 With Carboplatin, Paclitaxel and Bevacizumab in Untreated Stage IIIb Non-small Cell Lung Cancer (NSCLC)
Study of BAY43-9006 (Sorafenib) in Combination With Carboplatin, Paclitaxel and Bevacizumab in Previously Untreated Patients With Stage IIIB (With Malignant Pleural Effusions) or Stage IV Non-small Cell Lung Cancer (NSCLC)
Status: Archived
Clinical Trial Facility
mi
from
Austin, TX
Dose Escalating Study With BAY43-9006 With Carboplatin, Paclitaxel and Bevacizumab in Untreated Stage IIIb Non-small Cell Lung Cancer (NSCLC)
Study of BAY43-9006 (Sorafenib) in Combination With Carboplatin, Paclitaxel and Bevacizumab in Previously Untreated Patients With Stage IIIB (With Malignant Pleural Effusions) or Stage IV Non-small Cell Lung Cancer (NSCLC)
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Austin, TX
Study of Sunitinib in Subjects With High Risk Renal Cell Carcinoma
Phase II, Open Label, Single Center Study of Sunitinib in Subjects With High Risk Renal Cell Carcinoma
Status: Archived
David Geffen School of Medicine, UCLA
mi
from
Los Angeles, CA
Study of Sunitinib in Subjects With High Risk Renal Cell Carcinoma
Phase II, Open Label, Single Center Study of Sunitinib in Subjects With High Risk Renal Cell Carcinoma
Status: Archived
Updated: 1/1/1970
David Geffen School of Medicine, UCLA
mi
from
Los Angeles, CA
Investigating the Needs of Childhood Cancer Survivors: The Unreported Experience
Investigating the Needs of Childhood Cancer Survivors: The Unreported Experience
Status: Archived
St. Jude Childrens Research Hosp, Memphis
mi
from
Memphis, TN
Investigating the Needs of Childhood Cancer Survivors: The Unreported Experience
Investigating the Needs of Childhood Cancer Survivors: The Unreported Experience
Status: Archived
Updated: 1/1/1970
St. Jude Childrens Research Hosp, Memphis
mi
from
Memphis, TN
Investigating the Needs of Childhood Cancer Survivors: The Unreported Experience
Investigating the Needs of Childhood Cancer Survivors: The Unreported Experience
Status: Archived
Fred Hutchinson Cancer Research Center
mi
from
Seattle, WA
Investigating the Needs of Childhood Cancer Survivors: The Unreported Experience
Investigating the Needs of Childhood Cancer Survivors: The Unreported Experience
Status: Archived
Updated: 1/1/1970
Fred Hutchinson Cancer Research Center
mi
from
Seattle, WA
A Safety and Efficacy Study of KX2-391 in Patients With Bone-Metastatic, Castration-Resistant Prostate Cancer Who Have Not Received Prior Chemotherapy
A Phase II, Open-Label, Single-Arm Study Evaluating the Safety, Efficacy and Pharmacokinetics of KX2-391 in Patients With Bone-Metastatic, Castration-Resistant Prostate Cancer Who Have Not Had Prior Chemotherapy
Status: Archived
University of Chicago
mi
from
Chicago, IL
A Safety and Efficacy Study of KX2-391 in Patients With Bone-Metastatic, Castration-Resistant Prostate Cancer Who Have Not Received Prior Chemotherapy
A Phase II, Open-Label, Single-Arm Study Evaluating the Safety, Efficacy and Pharmacokinetics of KX2-391 in Patients With Bone-Metastatic, Castration-Resistant Prostate Cancer Who Have Not Had Prior Chemotherapy
Status: Archived
Updated: 1/1/1970
University of Chicago
mi
from
Chicago, IL
A Safety and Efficacy Study of KX2-391 in Patients With Bone-Metastatic, Castration-Resistant Prostate Cancer Who Have Not Received Prior Chemotherapy
A Phase II, Open-Label, Single-Arm Study Evaluating the Safety, Efficacy and Pharmacokinetics of KX2-391 in Patients With Bone-Metastatic, Castration-Resistant Prostate Cancer Who Have Not Had Prior Chemotherapy
Status: Archived
Johns Hopkins University
mi
from
Baltimore, MD
A Safety and Efficacy Study of KX2-391 in Patients With Bone-Metastatic, Castration-Resistant Prostate Cancer Who Have Not Received Prior Chemotherapy
A Phase II, Open-Label, Single-Arm Study Evaluating the Safety, Efficacy and Pharmacokinetics of KX2-391 in Patients With Bone-Metastatic, Castration-Resistant Prostate Cancer Who Have Not Had Prior Chemotherapy
Status: Archived
Updated: 1/1/1970
Johns Hopkins University
mi
from
Baltimore, MD
A Safety and Efficacy Study of KX2-391 in Patients With Bone-Metastatic, Castration-Resistant Prostate Cancer Who Have Not Received Prior Chemotherapy
A Phase II, Open-Label, Single-Arm Study Evaluating the Safety, Efficacy and Pharmacokinetics of KX2-391 in Patients With Bone-Metastatic, Castration-Resistant Prostate Cancer Who Have Not Had Prior Chemotherapy
Status: Archived
Wayne State University
mi
from
Detroit, MI
A Safety and Efficacy Study of KX2-391 in Patients With Bone-Metastatic, Castration-Resistant Prostate Cancer Who Have Not Received Prior Chemotherapy
A Phase II, Open-Label, Single-Arm Study Evaluating the Safety, Efficacy and Pharmacokinetics of KX2-391 in Patients With Bone-Metastatic, Castration-Resistant Prostate Cancer Who Have Not Had Prior Chemotherapy
Status: Archived
Updated: 1/1/1970
Wayne State University
mi
from
Detroit, MI
A Safety and Efficacy Study of KX2-391 in Patients With Bone-Metastatic, Castration-Resistant Prostate Cancer Who Have Not Received Prior Chemotherapy
A Phase II, Open-Label, Single-Arm Study Evaluating the Safety, Efficacy and Pharmacokinetics of KX2-391 in Patients With Bone-Metastatic, Castration-Resistant Prostate Cancer Who Have Not Had Prior Chemotherapy
Status: Archived
University of Washington
mi
from
Seattle, WA
A Safety and Efficacy Study of KX2-391 in Patients With Bone-Metastatic, Castration-Resistant Prostate Cancer Who Have Not Received Prior Chemotherapy
A Phase II, Open-Label, Single-Arm Study Evaluating the Safety, Efficacy and Pharmacokinetics of KX2-391 in Patients With Bone-Metastatic, Castration-Resistant Prostate Cancer Who Have Not Had Prior Chemotherapy
Status: Archived
Updated: 1/1/1970
University of Washington
mi
from
Seattle, WA
A Safety and Efficacy Study of KX2-391 in Patients With Bone-Metastatic, Castration-Resistant Prostate Cancer Who Have Not Received Prior Chemotherapy
A Phase II, Open-Label, Single-Arm Study Evaluating the Safety, Efficacy and Pharmacokinetics of KX2-391 in Patients With Bone-Metastatic, Castration-Resistant Prostate Cancer Who Have Not Had Prior Chemotherapy
Status: Archived
University of Wisconsin-Madison
mi
from
Madison, WI
A Safety and Efficacy Study of KX2-391 in Patients With Bone-Metastatic, Castration-Resistant Prostate Cancer Who Have Not Received Prior Chemotherapy
A Phase II, Open-Label, Single-Arm Study Evaluating the Safety, Efficacy and Pharmacokinetics of KX2-391 in Patients With Bone-Metastatic, Castration-Resistant Prostate Cancer Who Have Not Had Prior Chemotherapy
Status: Archived
Updated: 1/1/1970
University of Wisconsin-Madison
mi
from
Madison, WI
Ixabepilone + Carboplatin Metastatic Breast Cancer
Phase II Trial of Ixabepilone Plus Carboplatin in Patients With Metastatic Breast Cancer: The ECLIPSE Study
Status: Archived
Hematology Oncology Associates
mi
from
Phoenix, AZ
Ixabepilone + Carboplatin Metastatic Breast Cancer
Phase II Trial of Ixabepilone Plus Carboplatin in Patients With Metastatic Breast Cancer: The ECLIPSE Study
Status: Archived
Updated: 1/1/1970
Hematology Oncology Associates
mi
from
Phoenix, AZ
Ixabepilone + Carboplatin Metastatic Breast Cancer
Phase II Trial of Ixabepilone Plus Carboplatin in Patients With Metastatic Breast Cancer: The ECLIPSE Study
Status: Archived
Northern Arizona Hematology & Oncology Associates
mi
from
Sedona, AZ
Ixabepilone + Carboplatin Metastatic Breast Cancer
Phase II Trial of Ixabepilone Plus Carboplatin in Patients With Metastatic Breast Cancer: The ECLIPSE Study
Status: Archived
Updated: 1/1/1970
Northern Arizona Hematology & Oncology Associates
mi
from
Sedona, AZ